前列腺与转移灶定向放疗联合治疗新发寡转移性前列腺癌的临床结局
中位随访27个月,2年远处转移累积发生率32%,总生存87%。放疗后PSA不可测与较低生化复发和远处转移风险相关,部分患者可停用ADT并获得非去势缓解。
要点
- 综合PDRT+ORT策略在新发寡转移性前列腺癌中显示良好临床结局。
- 放疗后PSA不可测者生化复发和远处转移风险显著降低。
- 部分患者可停用ADT并维持非去势缓解,中位非去势持续时间8个月。
核心结论
- 基于放疗的综合治疗策略在新发寡转移性前列腺癌中具有良好临床结局,可使部分患者获得长期非去势缓解。
研究设计与样本
- 从放疗开始计算结局,采用Kaplan-Meier、竞争风险和Cox回归分析,中位随访27个月(95%CI 16-42)。
主要发现
- 放疗后1年和2年远处转移进展累积发生率分别为21%和32%,总生存分别为90%和87%。
- 神经内分泌/导管内组织学、PSA<20及PDRT+ORT后PSA可测与远处转移进展风险增加相关,寡转移灶数目和位置无关。
- 局部失败罕见,随访期间前列腺复发3例,10个治疗寡转移灶进展。
- 新辅助ADT后9例(19%)PSA不可测(<0.05 ng/mL),PDRT+ORT后增至32例(68%)。
关键数值与推荐
- PSA不可测定义为<0.05 ng/mL;睾酮恢复定义为>150 ng/dL。
- 远处转移进展风险增加相关因素:神经内分泌/导管内组织学、PSA<20、PDRT+ORT后PSA可测。
临床怎么用
- 对新发寡转移性前列腺癌可考虑ADT联合PDRT和ORT的综合放疗策略。
- 放疗后PSA不可测提示较好预后,可作为疗效监测指标。
- 部分患者可尝试停用ADT并监测睾酮和PSA,实现非去势缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial reported overall survival benefits for prostate-directed radiation therapy (PDRT) in low-burden metastatic prostate cancer. Oligometastasis-directed radiation therapy (ORT) improves androgen deprivation therapy (ADT)-free and progression-free survivals. Comprehensive PDRT + ORT to all detectable metastases may offer benefit for de novo oligometastatic prostate cancer (DNOPC) and is under prospective study; given few available benchmarks, we reviewed our institutional experience. METHODS AND MATERIALS: Forty-seven patients with DNOPC with predominantly M1b disease received neoadjuvant, concurrent, and adjuvant ADT plus PDRT + ORT to 1 to 6 oligometastases. Gross pelvic (N1) nodes were not considered oligometastases unless focally targeted without broader nodal coverage. Outcomes were analyzed from radiation therapy (RT) start using Kaplan-Meier, competing risks, and Cox regression. Median follow-up was 27 (95% confidence interval, 16-42) months. RESULTS: At 1- and 2-years post-RT, cumulative incidence of distant metastatic progression (DMP) was 21% and 32%, whereas overall survival was 90% and 87%, respectively. Neuroendocrine/intraductal histology, prostate-specific antigen (PSA) < 20, and detectable PSA after PDRT + ORT were associated with increased DMP risk; number and location of oligometastases were not. Local failure was rare, with 3 prostate recurrences and progression of 10 treated oligometastases during follow-up. After neoadjuvant ADT, 9 (19%) patients had undetectable PSA (<0.05 ng/mL), which increased to 32 (68%) after PDRT + ORT. Overall 2-year incidence of biochemical recurrence (BCR) and development of castrate resistance were 23% and 36%, respectively. Undetectable PSA post-RT was associated with lower risk of BCR (hazard ratio, 0.19; P = .004) and DMP (hazard ratio, 0.26; P = .025). Overall, 23 (49%) patients were trialed off ADT; 16 (70%) had testosterone recovery (>150 ng/dL) and, of these, 5 had subsequent PSA rise and restarted ADT 2 to 21 months postrecovery. The remaining 11 were maintained off ADT without BCR. Median noncastrate duration was 8 months; 7 patients had normalized testosterone for >1 year. CONCLUSIONS: A comprehensive, radiotherapeutic-based treatment strategy has favorable clinical outcomes and can produce prolonged noncastrate remissions in a subset with DNOPC.
引用
- Imber BS, Varghese M, Goldman DA, et al. Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer. Adv Radiat Oncol. 2020. PMID: 33305082. doi:10.1016/j.adro.2020.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。